(Total Views: 440)
Posted On: 09/10/2021 1:28:10 PM
Post# of 153874
Disappointing to see lackluster response to initiation of a Phase 3 trial for severe COVID treatment. However, entirely expected. Poor timing - a day after a critical-for-management conference call. Plus of course a proxy fight.
As CYDY has "overshared" for years there is little news they can announce that will significantly move the needle, except for hard facts: irrefutable, readily and independently verifiable clinical RESULTS. A BTD, NASH results or a EUA might do the trick.
3D is may be on their way to oversharing as well. Last conference call, while really informative with very interesting insights to cydy management, scientific and financial activity, was long and felt unfocused. Sharpen up the marketing/comms game folks.
Frankly, in the next 6 weeks I don't care what is said by who- only what happens. If the share price is heading to or over $5 on October 26 management has my vote, if not, see ya.
The measure of success is SP.
As CYDY has "overshared" for years there is little news they can announce that will significantly move the needle, except for hard facts: irrefutable, readily and independently verifiable clinical RESULTS. A BTD, NASH results or a EUA might do the trick.
3D is may be on their way to oversharing as well. Last conference call, while really informative with very interesting insights to cydy management, scientific and financial activity, was long and felt unfocused. Sharpen up the marketing/comms game folks.
Frankly, in the next 6 weeks I don't care what is said by who- only what happens. If the share price is heading to or over $5 on October 26 management has my vote, if not, see ya.
The measure of success is SP.
(0)
(1)
